Erythropoietin-mediated neuroprotection in a pediatric mouse model of chronic hypoxia

Eugene Chung, Xiangmei Kong, Mark P. Goldberg, Ann M. Stowe, Lakshmi Raman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Chronic hypoxia (CH), a disease state that accounts for significant morbidity and mortality in pediatrics, occurs in many children during critical periods of hippocampal development and cortical myelination. Hippocampal neurogenesis occurs throughout postnatal life and is important for normal development, thus impairment results in long-term cognitive deficits. Erythropoietin (EPO), a drug commonly known for its role in erythrogenesis, has recently been evaluated in neuroprotection in neonatal injury models and preterm brain injury. However, the effects of EPO therapy on hippocampal neurogenesis and myelination in pediatric CH are unknown. We show that CH decreases hippocampal neurogenesis in a pediatric mouse model. This decrease in early and late progenitors, and actively dividing cells is rescued with EPO treatment. Furthermore, we show that CH during this critical time decreases oligodendrocyte progenitor (OPC) populations in the cortex, leading to defective myelination. However, EPO therapy is only able to rescue the OPC but not the loss of mature myelin. Overall, our findings demonstrate that CH in developing mice has significant effects on hippocampal neurogenesis and OPCs, which can be rescued with EPO treatment. Future studies should confirm the role of this FDA-approved therapy in neuroprotection in at-risk pediatric populations.

Original languageEnglish (US)
Pages (from-to)54-59
Number of pages6
JournalNeuroscience Letters
Volume597
DOIs
StatePublished - Jun 5 2015

Fingerprint

Erythropoietin
Neurogenesis
Pediatrics
Therapeutics
Oligodendroglia
Myelin Sheath
Brain Injuries
Neuroprotection
Hypoxia
Morbidity
Mortality
Wounds and Injuries
Pharmaceutical Preparations
Population

Keywords

  • Chronic hypoxia
  • Dentate gyrus
  • Erythropoietin
  • Myelin
  • Neurogenesis
  • Oligodendrocyte progenitors

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Erythropoietin-mediated neuroprotection in a pediatric mouse model of chronic hypoxia. / Chung, Eugene; Kong, Xiangmei; Goldberg, Mark P.; Stowe, Ann M.; Raman, Lakshmi.

In: Neuroscience Letters, Vol. 597, 05.06.2015, p. 54-59.

Research output: Contribution to journalArticle

@article{bf1c3de7a51c4b31b6fdda6adead6272,
title = "Erythropoietin-mediated neuroprotection in a pediatric mouse model of chronic hypoxia",
abstract = "Chronic hypoxia (CH), a disease state that accounts for significant morbidity and mortality in pediatrics, occurs in many children during critical periods of hippocampal development and cortical myelination. Hippocampal neurogenesis occurs throughout postnatal life and is important for normal development, thus impairment results in long-term cognitive deficits. Erythropoietin (EPO), a drug commonly known for its role in erythrogenesis, has recently been evaluated in neuroprotection in neonatal injury models and preterm brain injury. However, the effects of EPO therapy on hippocampal neurogenesis and myelination in pediatric CH are unknown. We show that CH decreases hippocampal neurogenesis in a pediatric mouse model. This decrease in early and late progenitors, and actively dividing cells is rescued with EPO treatment. Furthermore, we show that CH during this critical time decreases oligodendrocyte progenitor (OPC) populations in the cortex, leading to defective myelination. However, EPO therapy is only able to rescue the OPC but not the loss of mature myelin. Overall, our findings demonstrate that CH in developing mice has significant effects on hippocampal neurogenesis and OPCs, which can be rescued with EPO treatment. Future studies should confirm the role of this FDA-approved therapy in neuroprotection in at-risk pediatric populations.",
keywords = "Chronic hypoxia, Dentate gyrus, Erythropoietin, Myelin, Neurogenesis, Oligodendrocyte progenitors",
author = "Eugene Chung and Xiangmei Kong and Goldberg, {Mark P.} and Stowe, {Ann M.} and Lakshmi Raman",
year = "2015",
month = "6",
day = "5",
doi = "10.1016/j.neulet.2015.04.026",
language = "English (US)",
volume = "597",
pages = "54--59",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Erythropoietin-mediated neuroprotection in a pediatric mouse model of chronic hypoxia

AU - Chung, Eugene

AU - Kong, Xiangmei

AU - Goldberg, Mark P.

AU - Stowe, Ann M.

AU - Raman, Lakshmi

PY - 2015/6/5

Y1 - 2015/6/5

N2 - Chronic hypoxia (CH), a disease state that accounts for significant morbidity and mortality in pediatrics, occurs in many children during critical periods of hippocampal development and cortical myelination. Hippocampal neurogenesis occurs throughout postnatal life and is important for normal development, thus impairment results in long-term cognitive deficits. Erythropoietin (EPO), a drug commonly known for its role in erythrogenesis, has recently been evaluated in neuroprotection in neonatal injury models and preterm brain injury. However, the effects of EPO therapy on hippocampal neurogenesis and myelination in pediatric CH are unknown. We show that CH decreases hippocampal neurogenesis in a pediatric mouse model. This decrease in early and late progenitors, and actively dividing cells is rescued with EPO treatment. Furthermore, we show that CH during this critical time decreases oligodendrocyte progenitor (OPC) populations in the cortex, leading to defective myelination. However, EPO therapy is only able to rescue the OPC but not the loss of mature myelin. Overall, our findings demonstrate that CH in developing mice has significant effects on hippocampal neurogenesis and OPCs, which can be rescued with EPO treatment. Future studies should confirm the role of this FDA-approved therapy in neuroprotection in at-risk pediatric populations.

AB - Chronic hypoxia (CH), a disease state that accounts for significant morbidity and mortality in pediatrics, occurs in many children during critical periods of hippocampal development and cortical myelination. Hippocampal neurogenesis occurs throughout postnatal life and is important for normal development, thus impairment results in long-term cognitive deficits. Erythropoietin (EPO), a drug commonly known for its role in erythrogenesis, has recently been evaluated in neuroprotection in neonatal injury models and preterm brain injury. However, the effects of EPO therapy on hippocampal neurogenesis and myelination in pediatric CH are unknown. We show that CH decreases hippocampal neurogenesis in a pediatric mouse model. This decrease in early and late progenitors, and actively dividing cells is rescued with EPO treatment. Furthermore, we show that CH during this critical time decreases oligodendrocyte progenitor (OPC) populations in the cortex, leading to defective myelination. However, EPO therapy is only able to rescue the OPC but not the loss of mature myelin. Overall, our findings demonstrate that CH in developing mice has significant effects on hippocampal neurogenesis and OPCs, which can be rescued with EPO treatment. Future studies should confirm the role of this FDA-approved therapy in neuroprotection in at-risk pediatric populations.

KW - Chronic hypoxia

KW - Dentate gyrus

KW - Erythropoietin

KW - Myelin

KW - Neurogenesis

KW - Oligodendrocyte progenitors

UR - http://www.scopus.com/inward/record.url?scp=84928621103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928621103&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2015.04.026

DO - 10.1016/j.neulet.2015.04.026

M3 - Article

C2 - 25899777

AN - SCOPUS:84928621103

VL - 597

SP - 54

EP - 59

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

ER -